Key regions: Germany, South Korea, France, United States, United Kingdom
The Anti-Coagulants market in Netherlands has seen significant growth in recent years, driven by several factors including customer preferences for innovative treatments and local special circumstances.
Customer preferences: Patients in the Netherlands have shown a preference for new and innovative treatments, particularly those that offer improved efficacy and safety. This has led to an increase in demand for direct oral anticoagulants (DOACs) as they offer several advantages over traditional anticoagulants such as warfarin. DOACs have a faster onset of action, require less monitoring and have fewer food and drug interactions.
Trends in the market: The Anti-Coagulants market in Netherlands has seen a shift towards DOACs in recent years, with these drugs accounting for an increasing share of the market. This trend is expected to continue as more DOACs become available and as physicians become more comfortable prescribing them. Additionally, the market is expected to see increased competition as more generics become available for traditional anticoagulants such as warfarin.
Local special circumstances: The Netherlands has a well-developed healthcare system that places a strong emphasis on cost-effectiveness. This has led to the adoption of several policies that have influenced the Anti-Coagulants market. For example, the government has implemented a reference pricing system that sets a maximum price for certain drugs, including anticoagulants. This has led to increased competition among manufacturers to offer lower prices, which has benefited patients.
Underlying macroeconomic factors: The Anti-Coagulants market in Netherlands is also influenced by several macroeconomic factors. The aging population in the country has led to an increase in the prevalence of conditions such as atrial fibrillation, which is a major indication for anticoagulant therapy. Additionally, the Dutch healthcare system provides universal coverage, which has ensured that patients have access to the latest treatments. Finally, the country's strong economy has allowed for increased investment in healthcare infrastructure, which has supported the growth of the Anti-Coagulants market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
